This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Apr 2020

Aptar Pharma partners with Sonmol on digital platform for respiratory-related therapies

The collaboration will focus on bringing together connected drug delivery devices and the digital platform for asthma and COPD in China and other Asian markets.

AptarGroup and Sonmol, a leading Chinese digital respiratory therapeutics company, are collaborating to develop a digital therapies and services platform targeting respiratory and other diseases.

This collaboration will initially focus on bringing together connected drug delivery devices and the digital platform for asthma and chronic obstructive pulmonary disease (COPD). They will work together on expanding Sonmol’s platform services to enable remote patient monitoring, improve patient and physician interactions, increase patient engagement and adherence, and improve health outcomes.

The partnership will work with pharmaceutical and healthcare partners to accelerate the development, manufacturing, commercialization and supply of digital respiratory medicines, diagnostics and patient support services in China and other Asian markets for marketed and pipeline drugs.

The collaboration significantly bolster’s Aptar’s digital health offerings in Asia by combining Aptar Pharma’s expertise in connected drug delivery device development, innovation and quality manufacturing together with Sonmol’s connected devices, data platform and patient management services.

Sonmol, which is based in Shanghai, was founded in 2014 by Luffy Lv and a core team of software, algorithm and medical experts. Sonmol’s strategic focus is on chronic respiratory diseases, which is the second largest disease category in China. Government initiatives to push for early detection and prevention measures for chronic respiratory diseases strengthen the case for Smart Inhalers and connected devices as platforms to improve health conditions in patients, rectify the use of medications, improve inhaler adherence and provide better treatment outcomes for patients.

Aptar Pharma and Sonmol will co-build the ecosystem of connected healthcare devices and services for China and other markets, and collaborate on device development and manufacturing for local and global markets. Sonmol will focus on data and software development for China.

In addition to the partnership, Aptar Pharma has made a strategic equity investment in Sonmol during their latest round of funding.

Mentioned Companies
Aptar Pharma
View company profile

Related News